article thumbnail

What will shape the Pharma landscape in Q3 2025?

European Pharmaceutical Review

The findings suggest that the fibroblast growth factor receptor 2b (FGFR2b)-targeted monoclonal antibody bemarituzumab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival. The post What will shape the Pharma landscape in Q3 2025?

article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

Published July 8, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 5 min This audio is auto-generated. The results marked a major step for a disease with a 67% six-month survival rate using standard chemotherapies. By Amy Baxter • July 7, 2025 Keep up with the story.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

World-first legislation backs decentralised manufacturing

European Pharmaceutical Review

The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 reduces waiting times and boosts access to innovative therapies, MHRA explained. These therapies, such as CAR-T cancer therapy, have previously been produced in specialist facilities often far away from patients, resulting in treatment delays.

article thumbnail

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

Published June 6, 2025 Michael Gibney Senior Editor & Writer post share post print email license Permission granted by Daiichi Sankyo Listen to the article 8 min This audio is auto-generated. At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug.

article thumbnail

ASCO 2025: Informing Treatment Decisions Using a 14-Gene Assay in Early-Stage NSCLC

Pharmacy Times

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

article thumbnail

ALX Oncology’s ALX2004 gains FDA IND clearance to treat solid tumours

Pharmaceutical Business Review

Based on the FDA clearance, the company anticipates the commencement of Phase I clinical trials for ALX2004 in mid-2025. We meticulously designed all aspects of ALX2004 the antibody backbone, linker and payload to optimise the targeted delivery of a powerful chemotherapy payload to tumour cells while minimising systemic toxicity.

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, showcased significant advances across a range of malignancies, with novel agents, biomarker-driven strategies, and long-term outcomes data offering new insights into cancer treatment with implications for pharmacy practice. months; HR, 0.60; 95% CI, 0.47-0.77);